KF
RARE icon

Krilogy Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Krilogy Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$5K – 513
2018
Q1 		$5K Hold
100
– – ﹤0.01% 602
2017
Q4 		$5K Hold
100
– – ﹤0.01% 604
2017
Q3 		$5K Hold
100
– – ﹤0.01% 657
2017
Q2 		$6K Buy
+100
New +$6.03K ﹤0.01% 582

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Krilogy Financial's RARE Position: Q2 2018 in Review

Krilogy Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 100 shares — an estimated $5K sold.

Krilogy Financial first reported a position in RARE in Q2 2017 and held it in 4 quarters. The position peaked at $6K in Q2 2017. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

  • Krilogy Financial reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
  • Krilogy Financial sold 100 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $5K.
  • Krilogy Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 4 quarters.
  • Krilogy Financial's Ultragenyx Pharmaceutical position peaked at $6K in Q2 2017.
  • 158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on Krilogy Financial's 13F filing for Q2 2018, filed 15 Aug 2018.